Consensus $293.89M. The company said, “In alignment with our capital allocation priorities and M&A strategy, we closed the Previse tuck-in acquisition and announced an exciting collaboration and license agreement with SciBase, both of which we believe will support our mid- to long-term value creation goals. At the same time, we remain deeply focused on execution across our current test portfolio, which we believe positions us well for continued near-term success. Our ability to invest in the future while advancing our core franchises reflects the strength of our growth initiatives and commitment to delivering sustainable value to our stakeholders.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- CSTL Earnings this Week: How Will it Perform?
- Castle Biosciences announces DecisionDx-Melanoma test granted BD designation
- Castle Biosciences’ Strategic Partnership with SciBase: A Low-Risk Growth Opportunity in Atopic Dermatitis Testing
- Castle Biosciences enters collaboration, license agreement with SciBase
- Castle Biosciences management to meet virtually with Lake Street